NICE wants more info on rivaroxaban for AF . . .

Author：

ISSN： 1173-5503

Source： PharmacoEconomics and Outcomes News, Vol.1, Iss.645, 2012-01, pp. : 11-11

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Positive NICE recommendations for rivaroxaban and denosumab

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 651, 2012-01 ,pp. : 11-11

Adis International

Access to resources Recommend Favorite

NICE gives thumbs up to rivaroxaban

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 655, 2012-01 ,pp. : 10-10

Adis International

Access to resources Recommend Favorite

Amiodarone more effective but propafenone safer in recurrent AF

Inpharma, Vol. 1, Iss. 1430, 2004-01 ,pp. : 18-18

Adis International

Access to resources Recommend Favorite

NICE, nursing and the NHS: more news from the UK

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 259, 2000-01 ,pp. : 11-11

Adis International

Access to resources Recommend Favorite

NICE has increased its capacity for appraising new drugs and treatments, and will be able to review existing NICE appraisals more quickly

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 592, 2009-01 ,pp. : 10-10

Adis International

Access to resources Recommend Favorite